# Clinical trial results:
# A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia

## Summary

| | |
|---|---|
| EudraCT number | 2021-000688-57 |
| Trial protocol | HU PL |
| Global end of trial date | 14 August 2023 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 28 August 2024 |
| First version publication date | 28 August 2024 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | AROAPOC3-2002 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04998201 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Arrowhead Pharmaceuticals, Inc. |
| Sponsor organisation address | 177 East Colorado Boulevard, Suite 700, Pasadena, CA, United States, 91105 |
| Public contact | Chief Operating Officer, Arrowhead Pharmaceuticals, Inc., +1 626-304-3400, info@arrowheadpharma.com |
| Scientific contact | Chief Operating Officer, Arrowhead Pharmaceuticals, Inc., +1 626-304-3400, info@arrowheadpharma.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 14 August 2023 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 14 August 2023 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study was to evaluate the safety and efficacy of ARO-APOC3 in adults with mixed dyslipidemia (MD) and to select a dose and dosing regimen for later stage clinical studies in this patient population.

Protection of trial subjects:

All eligible participants had the study explained by the PI or designee. They received a full explanation, in lay terms, of the aims of the study, the discomforts, risks and benefits in taking part as well as of insurance and other procedures for compensation in case of injury. It was explained that the study is for research purposes only and was not expected to provide any therapeutic benefit to the individual. It was pointed out that they could withdraw from the study at any time without prejudice.

Background therapy:

All subjects were required to maintain a stable regimen of optimal statin therapy during screening and throughout the treatment period.

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 07 September 2021 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Canada: 38 |
| Country: Number of subjects enrolled | Australia: 10 |
| Country: Number of subjects enrolled | New Zealand: 12 |
| Country: Number of subjects enrolled | United States: 169 |
| Country: Number of subjects enrolled | Poland: 18 |
| Country: Number of subjects enrolled | Hungary: 106 |
| Worldwide total number of subjects | 353 |
| EEA total number of subjects | 124 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|---|---|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 206 |
| From 65 to 84 years | 145 |
| 85 years and over | 2 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Participants who successfully passed the requirements during the Screening period were enrolled into the study. All dose cohorts were enrolled in parallel with participants randomized 3:1 to receive ARO-APOC3 or placebo.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Subject |

Blinding implementation details:

Treatment assignment (active versus placebo) was blinded in this clinical study. Dose group assignment was not blinded, due to required injection volume differences dictated by the respective dose group. Therefore, participants received an injection of either active or placebo volume matched to the assigned dose group. Syringes were blinded in the Pharmacy with translucent wrapping to mask the blinded staff and participants to treatment assignment in accordance with instructions provided.

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Placebo |

Arm description:

Volume-matched placebo at Day 1 and Week 12

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subcutaneous (SC) injection on Day 1 and Week 12 for a total of 2 injections

| | |
|---|---|
| **Arm title** | ARO-APOC3 10 mg Q12W |

Arm description:

ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W)

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | ARO-APOC3 Injection |
| Investigational medicinal product code | ARO-APOC3 |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

SC injection on Day 1 and Week 12 for a total of 2 injections

| | |
|---|---|
| **Arm title** | ARO-APOC3 25mg Q12W |

Arm description:

ARO-APOC3 25 mg  at Day 1 and Week 12 (Q12W)

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | ARO-APOC3 Injection |
| Investigational medicinal product code | ARO-APOC3 |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

SC injection on Day 1 and Week 12 for a total of 2 injections

| | |
|---|---|
| **Arm title** | ARO-APOC3 50mg Q12W |

Arm description:

ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W)

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | ARO-APOC3 Injection |
| Investigational medicinal product code | ARO-APOC3 |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

SC injection on Day 1 and Week 12 for a total of 2 injections

| | |
|---|---|
| **Arm title** | ARO-APOC3 50mg Q24W |

Arm description:

ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W)

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | ARO-APOC3 Injection |
| Investigational medicinal product code | ARO-APOC3 |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

SC injection on Day 1 and Week 24 for a total of 2 injections

| **Number of subjects in period 1** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W |
|---|---|---|---|
| Started | 87 | 67 | 67 |
| Completed | 78 | 60 | 64 |
| Not completed | 9 | 7 | 3 |
| Consent withdrawn by subject | 3 | 3 | 1 |
| Physician decision | 3 | 1 | - |
| Death | - | - | 1 |
| Other, not specified | - | - | - |
| Adverse event | - | 1 | - |
| Lost to follow-up | 2 | 2 | 1 |
| Protocol deviation | 1 | - | - |

| **Number of subjects in period 1** | ARO-APOC3 50mg Q12W | ARO-APOC3 50mg Q24W |
|---|---|---|
| Started | 66 | 66 |

| | | |
|---|---|---|
| Completed | 61 | 61 |
| Not completed | 5 | 5 |
| Consent withdrawn by subject | 1 | 2 |
| Physician decision | 2 | - |
| Death | - | 1 |
| Other, not specified | - | 1 |
| Adverse event | - | 1 |
| Lost to follow-up | 1 | - |
| Protocol deviation | 1 | - |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Placebo |
| Reporting group description: | |
| Volume-matched placebo at Day 1 and Week 12 | |
| Reporting group title | ARO-APOC3 10 mg Q12W |
| Reporting group description: | |
| ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 25mg Q12W |
| Reporting group description: | |
| ARO-APOC3 25 mg  at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 50mg Q12W |
| Reporting group description: | |
| ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 50mg Q24W |
| Reporting group description: | |
| ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W) | |

| Reporting group values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W |
|---|---|---|---|
| Number of subjects | 87 | 67 | 67 |
| Age categorical<br>Units: Subjects | | | |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 58.9 | 60.2 | 61.3 |
| standard deviation | ± 9.70 | ± 11.71 | ± 11.28 |
| Gender categorical<br>Units: Subjects | | | |
| Female | 41 | 31 | 37 |
| Male | 46 | 36 | 30 |
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or Latino | 16 | 18 | 12 |
| Not Hispanic or Latino | 71 | 49 | 55 |
| Not Reported | 0 | 0 | 0 |
| Race<br>Units: Subjects | | | |
| White | 79 | 62 | 60 |
| Black or African American | 4 | 2 | 2 |
| American Indian or Alaska Native | 0 | 0 | 1 |
| Asian | 3 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 |
| Unknown | 0 | 0 | 0 |
| Other | 1 | 1 | 0 |

| | | | |
|---|---|---|---|
| Mean Triglycerides (TG) | | | |
| Units: mg/dL | | | |
| arithmetic mean | 237.22 | 253.15 | 234.08 |
| standard deviation | ± 76.179 | ± 81.425 | ± 72.746 |

| **Reporting group values** | ARO-APOC3 50mg Q12W | ARO-APOC3 50mg Q24W | Total |
|---|---|---|---|
| Number of subjects | 66 | 66 | 353 |
| Age categorical | | | |
| Units: Subjects | | | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 62.6 | 61.3 | |
| standard deviation | ± 10.53 | ± 11.84 | - |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 37 | 43 | 189 |
| Male | 29 | 23 | 164 |
| Ethnicity | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 12 | 15 | 73 |
| Not Hispanic or Latino | 53 | 51 | 279 |
| Not Reported | 1 | 0 | 1 |
| Race | | | |
| Units: Subjects | | | |
| White | 63 | 62 | 326 |
| Black or African American | 0 | 0 | 8 |
| American Indian or Alaska Native | 0 | 0 | 1 |
| Asian | 1 | 1 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 2 |
| Unknown | 0 | 1 | 1 |
| Other | 2 | 1 | 5 |
| Mean Triglycerides (TG) | | | |
| Units: mg/dL | | | |
| arithmetic mean | 250.25 | 248.01 | |
| standard deviation | ± 81.329 | ± 80.553 | - |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Placebo |
| Reporting group description: Volume-matched placebo at Day 1 and Week 12 | |
| Reporting group title | ARO-APOC3 10 mg Q12W |
| Reporting group description: ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 25mg Q12W |
| Reporting group description: ARO-APOC3 25 mg at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 50mg Q12W |
| Reporting group description: ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 50mg Q24W |
| Reporting group description: ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W) | |

### Primary: Percent Change From Baseline at Week 24 in Fasting TG

| | |
|---|---|
| End point title | Percent Change From Baseline at Week 24 in Fasting TG |
| End point description: Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases. | |
| End point type | Primary |
| End point timeframe: Baseline, Week 24 | |

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 81 | 61 | 63 | 62 |
| Units: percentage change | | | | |
| least squares mean (standard error) | -1.7 (± 3.07) | -51.5 (± 3.54) | -57.7 (± 3.49) | -64.1 (± 3.51) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 61 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | -45.9 (± 3.52) | | | |

## Statistical analyses

| **Statistical analysis title** | Statistical Analysis 1 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 10 mg Q12W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [1] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -49.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -59 |
| upper limit | -40.6 |

Notes:

[1] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

| **Statistical analysis title** | Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 25mg Q12W |
| Number of subjects included in analysis | 144 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [2] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -56 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -65.1 |
| upper limit | -46.8 |

Notes:

[2] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

| **Statistical analysis title** | Statistical Analysis 3 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q12W |

| | |
|---|---|
| Number of subjects included in analysis | 143 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [3] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -62.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -71.5 |
| upper limit | -53.2 |

Notes:

[3] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

| **Statistical analysis title** | Statistical Analysis 4 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q24W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [4] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -44.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -53.4 |
| upper limit | -35 |

Notes:

[4] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

## Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting TG

| End point title | Percent Change From Baseline Over Time Through Week 48 in Fasting TG |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Observed cases at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | -0.5 (± 2.77) | -51.4 (± 3.21) | -61.5 (± 3.14) | -66.4 (± 3.20) |
| Week 8; n=83, 64, 66, 64, 64 | -0.4 (± 2.45) | -48.6 (± 2.78) | -58.1 (± 2.77) | -65.0 (± 2.78) |
| Week 12; n=80, 63, 61, 64, 61 | -0.1 (± 3.07) | -43.8 (± 3.46) | -53.6 (± 3.50) | -57.9 (± 3.45) |
| Week 16; n=77, 63, 63, 63, 65 | -1.8 (± 2.87) | -58.0 (± 3.21) | -62.0 (± 3.21) | -68.3 (± 3.21) |
| Week 20; n=82, 59, 61, 61, 63 | 1.2 (± 2.85) | -54.6 (± 3.32) | -62.0 (± 3.28) | -64.7 (± 3.28) |
| Week 24; n=81, 61, 63, 62, 61 | -1.7 (± 3.07) | -51.5 (± 3.54) | -57.7 (± 3.49) | -64.1 (± 3.51) |
| Week 28; n=82, 61, 64, 62, 61 | 3.5 (± 2.95) | -46.2 (± 3.41) | -55.7 (± 3.35) | -61.7 (± 3.38) |
| Week 36; n=80, 61, 63, 60, 61 | 6.1 (± 4.66) | -44.7 (± 5.35) | -51.5 (± 5.25) | -54.9 (± 5.34) |
| Week 48; n=78, 60, 64, 61, 61 | 1.7 (± 4.35) | -33.2 (± 4.96) | -42.8 (± 4.86) | -50.2 (± 4.94) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | -62.5 (± 3.19) | | | |
| Week 8; n=83, 64, 66, 64, 64 | -59.7 (± 2.78) | | | |
| Week 12; n=80, 63, 61, 64, 61 | -51.7 (± 3.49) | | | |
| Week 16; n=77, 63, 63, 63, 65 | -50.6 (± 3.17) | | | |
| Week 20; n=82, 59, 61, 61, 63 | -49.1 (± 3.23) | | | |
| Week 24; n=81, 61, 63, 62, 61 | -45.9 (± 3.52) | | | |
| Week 28; n=82, 61, 64, 62, 61 | -63.4 (± 3.39) | | | |
| Week 36; n=80, 61, 63, 60, 61 | -60.1 (± 5.32) | | | |
| Week 48; n=78, 60, 64, 61, 61 | -55.0 (± 4.93) | | | |

| Attachments (see zip file) | Percent Change from Baseline Over Time Through Week 48 in |
|---|---|

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III

| End point title | Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Week 24

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 79 | 59 | 63 | 62 |
| Units: percentage change | | | | |
| least squares mean (standard error) | 23.9 (± 21.90) | -58.9 (± 24.86) | -44.3 (± 24.54) | -65.7 (± 24.71) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 61 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | -57.9 (± 24.70) | | | |

**Statistical analyses**

| Statistical analysis title | Statistical Analysis 1 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 10 mg Q12W |
| Number of subjects included in analysis | 138 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0128 [5] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -82.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -147.9 |
| upper limit | -17.7 |

Notes:

[5] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

| Statistical analysis title | Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 25mg Q12W |

| | |
|---|---|
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0387 [6] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -68.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -132.9 |
| upper limit | -3.5 |

Notes:

[6] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

| **Statistical analysis title** | Statistical Analysis 3 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q12W |
| Number of subjects included in analysis | 141 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0069 [7] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -89.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -154.5 |
| upper limit | -24.7 |

Notes:

[7] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

| **Statistical analysis title** | Statistical Analysis 4 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q24W |
| Number of subjects included in analysis | 140 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0136 [8] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -81.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -146.7 |
| upper limit | -16.9 |

Notes:

[8] - Mixed Model Repeated Measures (MMRM) model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms.

## Secondary: Percent Change From Baseline Over Time Through Week 48 in Apolipoprotein (Apo)C-III

| End point title | Percent Change From Baseline Over Time Through Week 48 in Apolipoprotein (Apo)C-III |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Observed cases at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=84, 61, 67, 63, 63 | 19.3 (± 21.81) | -60.7 (± 24.78) | -69.7 (± 24.45) | -78.4 (± 24.66) |
| Week 8; n=81, 63, 65, 64, 64 | 19.0 (± 21.84) | -57.3 (± 24.72) | -61.9 (± 24.48) | -71.8 (± 24.64) |
| Week 12; n=79, 62, 61, 64, 61 | 20.3 (± 21.90) | -48.7 (± 24.77) | -18.9 (± 24.57) | -59.2 (± 24.66) |
| Week 16; n=77, 62, 63, 64, 65 | 10.9 (± 21.92) | -69.9 (± 24.79) | -63.8 (± 24.54) | -78.9 (± 24.67) |
| Week 20; n=80, 58, 60, 61, 63 | 21.8 (± 21.88) | -64.0 (± 24.87) | -63.3 (± 24.58) | -69.3 (± 24.72) |
| Week 24; n=79, 59, 63, 62, 61 | 23.9 (± 21.90) | -58.9 (± 24.86) | -44.3 (± 24.54) | -65.7 (± 24.71) |
| Week 28; n=81, 60, 64, 62, 62 | 35.6 (± 21.90) | -51.7 (± 24.87) | -32.8 (± 24.55) | -53.3 (± 24.71) |
| Week 36; n=79, 60, 63, 60, 61 | 30.6 (± 21.96) | -46.3 (± 24.91) | -24.9 (± 24.58) | -34.5 (± 24.74) |
| Week 48; n=77, 59, 64, 61, 61 | 27.3 (± 21.97) | -31.2 (± 24.97) | -13.9 (± 24.58) | -17.4 (± 24.78) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=84, 61, 67, 63, 63 | -82.7 (± 24.64) | | | |
| Week 8; n=81, 63, 65, 64, 64 | -78.1 (± 24.62) | | | |
| Week 12; n=79, 62, 61, 64, 61 | -71.5 (± 24.68) | | | |

| | | | | |
|---|---|---|---|---|
| Week 16; n=77, 62, 63, 64, 65 | -67.7 (± 24.62) | | | |
| Week 20; n=80, 58, 60, 61, 63 | -62.6 (± 24.65) | | | |
| Week 24; n=79, 59, 63, 62, 61 | -57.9 (± 24.70) | | | |
| Week 28; n=81, 60, 64, 62, 62 | -82.5 (± 24.70) | | | |
| Week 36; n=79, 60, 63, 60, 61 | -75.8 (± 24.70) | | | |
| Week 48; n=77, 59, 64, 61, 61 | -64.8 (± 24.72) | | | |

| | |
|---|---|
| **Attachments (see zip file)** | Percent Change from Baseline at Week 24 and Over Time |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C)

| | |
|---|---|
| End point title | Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C) |

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline, Week 24

| **End point values** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 81 | 61 | 63 | 62 |
| Units: percentage change | | | | |
| least squares mean (standard error) | -2.7 (± 2.56) | -19.3 (± 2.93) | -20.1 (± 2.90) | -26.9 (± 2.92) |

| **End point values** | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 61 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | -10.3 (± 2.92) | | | |

## Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 10 mg Q12W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [9] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -16.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -24.3 |
| upper limit | -9 |

Notes:

[9] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| Statistical analysis title | Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 25mg Q12W |
| Number of subjects included in analysis | 144 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [10] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -17.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -25.1 |
| upper limit | -9.8 |

Notes:

[10] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| Statistical analysis title | Statistical Analysis 3 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q12W |
| Number of subjects included in analysis | 143 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [11] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -24.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -31.9 |
| upper limit | -16.6 |

Notes:

[11] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statistical Analysis 4 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q24W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0492 [12] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -7.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -15.3 |
| upper limit | 0 |

Notes:

[12] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

## Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C)

| End point title | Percent Change From Baseline Over Time Through Week 48 in Fasting Non-High-Density Lipoprotein Cholesterol (non-HDL-C) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Observed cases at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

| **End point values** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | -1.2 (± 2.19) | -17.3 (± 2.53) | -23.3 (± 2.48) | -26.3 (± 2.52) |
| Week 8; n=83, 64, 66, 64, 64 | -1.0 (± 2.37) | -18.2 (± 2.69) | -22.4 (± 2.67) | -27.8 (± 2.70) |
| Week 12; n=80, 63, 61, 64, 61 | -0.4 (± 2.65) | -15.5 (± 3.00) | -19.4 (± 3.01) | -21.9 (± 3.00) |
| Week 16; n=77, 63, 63, 63, 65 | -1.4 (± 2.49) | -21.2 (± 2.80) | -23.8 (± 2.80) | -28.5 (± 2.81) |
| Week 20; n=82, 59, 61, 61, 63 | -1.9 (± 2.82) | -20.9 (± 3.24) | -21.5 (± 3.21) | -27.3 (± 3.22) |
| Week 24; n=81, 61, 63, 62, 61 | -2.7 (± 2.56) | -19.3 (± 2.93) | -20.1 (± 2.90) | -26.9 (± 2.92) |
| Week 28; n=82, 61, 64, 62, 61 | 0.4 (± 2.91) | -17.1 (± 3.33) | -17.7 (± 3.29) | -25.6 (± 3.32) |
| Week 36; n=80, 61, 63, 60, 61 | 0.0 (± 2.71) | -17.1 (± 3.09) | -17.1 (± 3.05) | -23.4 (± 3.10) |
| Week 48; n=78, 60, 64, 61, 61 | 1.7 (± 2.96) | -12.1 (± 3.37) | -12.1 (± 3.29) | -21.8 (± 3.35) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | -19.6 (± 2.53) | | | |
| Week 8; n=83, 64, 66, 64, 64 | -16.2 (± 2.70) | | | |
| Week 12; n=80, 63, 61, 64, 61 | -16.0 (± 3.02) | | | |
| Week 16; n=77, 63, 63, 63, 65 | -15.5 (± 2.79) | | | |
| Week 20; n=82, 59, 61, 61, 63 | -11.7 (± 3.20) | | | |
| Week 24; n=81, 61, 63, 62, 61 | -10.3 (± 2.92) | | | |
| Week 28; n=82, 61, 64, 62, 61 | -20.5 (± 3.33) | | | |
| Week 36; n=80, 61, 63, 60, 61 | -17.3 (± 3.09) | | | |
| Week 48; n=78, 60, 64, 61, 61 | -20.0 (± 3.35) | | | |

| Attachments (see zip file) | Percent Change from Baseline at Week 24 and Over Time |
|---|---|

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)

| End point title | Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Observed cases.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Week 24

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 81 | 61 | 63 | 62 |
| Units: percentage change | | | | |
| least squares mean (standard error) | 4.7 (± 3.34) | 37.9 (± 3.81) | 46.8 (± 3.82) | 50.5 (± 3.80) |

| End point values | ARO-APOC3 | | | |
|---|---|---|---|---|

| | 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 61 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | 32.8 (± 3.82) | | | |

## Statistical analyses

| **Statistical analysis title** | Statistical Analysis 1 |
|---|---|
| Comparison groups | ARO-APOC3 10 mg Q12W v Placebo |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [13] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 33.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 23.2 |
| upper limit | 43.1 |

Notes:

[13] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 25mg Q12W |
| Number of subjects included in analysis | 144 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [14] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 42 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 32.1 |
| upper limit | 52 |

Notes:

[14] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statistical Analysis 3 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q12W |

| | |
|---|---|
| Number of subjects included in analysis | 143 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [15] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 45.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 35.8 |
| upper limit | 55.7 |

Notes:

[15] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statistical Analysis 4 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q24W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [16] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 28 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 18 |
| upper limit | 38 |

Notes:

[16] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

## Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)

| End point title | Percent Change From Baseline Over Time Through Week 48 in Fasting High-Density Lipoprotein Cholesterol (HDL-C) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Participants with an assessment at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | 3.6 (± 3.38) | 39.3 (± 3.88) | 48.3 (± 3.86) | 55.4 (± 3.88) |
| Week 8; n=83, 64, 66, 64, 64 | 2.0 (± 3.18) | 32.1 (± 3.61) | 46.4 (± 3.63) | 54.3 (± 3.62) |
| Week 12; n=80, 63, 61, 64, 61 | 2.5 (± 3.19) | 31.4 (± 3.60) | 40.1 (± 3.66) | 49.0 (± 3.61) |
| Week 16; n=77, 63, 63, 63, 65 | 3.2 (± 3.46) | 45.8 (± 3.90) | 56.4 (± 3.93) | 64.2 (± 3.91) |
| Week 20; n=82, 59, 61, 61, 63 | 2.8 (± 3.27) | 45.0 (± 3.75) | 50.6 (± 3.76) | 58.2 (± 3.74) |
| Week 24; n=81, 61, 63, 62, 61 | 4.7 (± 3.34) | 37.9 (± 3.81) | 46.8 (± 3.82) | 50.5 (± 3.80) |
| Week 28; n=82, 61, 64, 62, 61 | 2.1 (± 3.47) | 35.8 (± 3.98) | 45.3 (± 3.96) | 49.5 (± 3.96) |
| Week 36; n=80, 61, 63, 60, 61 | 1.6 (± 3.25) | 30.8 (± 3.72) | 37.0 (± 3.71) | 43.1 (± 3.72) |
| Week 48; n=78, 60, 64, 61, 61 | 4.5 (± 3.53) | 25.4 (± 4.02) | 30.5 (± 3.98) | 34.3 (± 4.00) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | 55.5 (± 3.90) | | | |
| Week 8; n=83, 64, 66, 64, 64 | 52.8 (± 3.64) | | | |
| Week 12; n=80, 63, 61, 64, 61 | 45.1 (± 3.65) | | | |
| Week 16; n=77, 63, 63, 63, 65 | 41.6 (± 3.91) | | | |
| Week 20; n=82, 59, 61, 61, 63 | 40.3 (± 3.73) | | | |
| Week 24; n=81, 61, 63, 62, 61 | 32.8 (± 3.82) | | | |
| Week 28; n=82, 61, 64, 62, 61 | 54.0 (± 3.99) | | | |
| Week 36; n=80, 61, 63, 60, 61 | 49.7 (± 3.73) | | | |
| Week 48; n=78, 60, 64, 61, 61 | 44.5 (± 4.01) | | | |

| Attachments (see zip file) | Percent Change from Baseline at Week 24 and Over Time |
|---|---|

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)

| End point title | Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Participants with an assessment at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Week 24

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 79 | 59 | 63 | 62 |
| Units: percentage change | | | | |
| least squares mean (standard error) | 0.8 (± 2.57) | -9.5 (± 2.94) | -12.2 (± 2.89) | -18.3 (± 2.91) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 61 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | -5.7 (± 2.91) | | | |

**Statistical analyses**

| Statistical analysis title | Statistical Analysis 1 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 10 mg Q12W |
| Number of subjects included in analysis | 138 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0089 [17] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -10.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -17.9 |
| upper limit | -2.6 |

Notes:

[17] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| Statistical analysis title | Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 25mg Q12W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0009 [18] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -13 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -20.6 |
| upper limit | -5.4 |

Notes:

[18] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statistical Analysis 3 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q12W |
| Number of subjects included in analysis | 141 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 [19] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -19.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -26.7 |
| upper limit | -11.5 |

Notes:

[19] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statistical Analysis 4 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q24W |
| Number of subjects included in analysis | 140 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0965 [20] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -6.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -14.1 |
| upper limit | 1.2 |

Notes:

[20] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

## Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting Total Apolipoprotein B (ApoB)

| End point title | Percent Change From Baseline Over Time Through Week 48 in Fasting Total Apolipoprotein B (ApoB) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Participants with an assessment at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

| **End point values** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=84, 61, 67, 63, 63 | -1.3 (± 1.99) | -10.3 (± 2.30) | -15.5 (± 2.24) | -18.5 (± 2.28) |
| Week 8; n=81, 63, 65, 64, 64 | -0.5 (± 2.26) | -11.0 (± 2.56) | -15.5 (± 2.54) | -20.3 (± 2.55) |
| Week 12; n=79, 62, 61, 64, 61 | 0.9 (± 2.53) | -8.5 (± 2.87) | -14.3 (± 2.86) | -14.8 (± 2.85) |
| Week 16; n=77, 62, 63, 64, 65 | 0.2 (± 2.30) | -12.8 (± 2.60) | -17.2 (± 2.57) | -20.6 (± 2.58) |
| Wek 20; n=80, 58, 60, 61, 63 | 0.5 (± 2.61) | -13.0 (± 3.00) | -14.3 (± 2.96) | -19.3 (± 2.97) |
| Week 24; n=79, 59, 63, 62, 61 | 0.8 (± 2.57) | -9.5 (± 2.94) | -12.2 (± 2.89) | -18.3 (± 2.91) |
| Week 28; n=81, 60, 64, 62, 62 | 5.1 (± 2.98) | -9.0 (± 3.41) | -10.0 (± 3.35) | -16.3 (± 3.38) |
| Week 36; n=79, 60, 63, 60, 61 | 3.7 (± 2.68) | -7.8 (± 3.07) | -9.3 (± 3.00) | -15.4 (± 3.05) |
| Week 48; n=77, 59, 64, 61, 61 | 3.3 (± 2.75) | -4.7 (± 3.14) | -6.4 (± 3.06) | -12.2 (± 3.11) |

| **End point values** | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=84, 61, 67, 63, 63 | -13.5 (± 2.29) | | | |
| Week 8; n=81, 63, 65, 64, 64 | -10.9 (± 2.56) | | | |
| Week 12; n=79, 62, 61, 64, 61 | -10.8 (± 2.87) | | | |
| Week 16; n=77, 62, 63, 64, 65 | -9.4 (± 2.58) | | | |
| Wek 20; n=80, 58, 60, 61, 63 | -7.3 (± 2.95) | | | |
| Week 24; n=79, 59, 63, 62, 61 | -5.7 (± 2.91) | | | |
| Week 28; n=81, 60, 64, 62, 62 | -12.1 (± 3.38) | | | |
| Week 36; n=79, 60, 63, 60, 61 | -9.9 (± 3.04) | | | |
| Week 48; n=77, 59, 64, 61, 61 | -11.9 (± 3.11) | | | |

| **Attachments (see zip file)** | Percent Change from Baseline at Week 24 and Over Time |
|---|---|

### Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)

| End point title | Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). Participants with an assessment at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Week 24

| **End point values** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 81 | 61 | 63 | 62 |
| Units: percentage change | | | | |
| least squares mean (standard error) | -0.1 (± 3.62) | 1.4 (± 4.14) | 3.9 (± 4.10) | -4.3 (± 4.13) |

| **End point values** | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 61 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | 7.3 (± 4.14) | | | |

**Statistical analyses**

| **Statistical analysis title** | Statisical Analysis 1 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 10 mg Q12W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.7856 [21] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 1.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -9.3 |
| upper limit | 12.3 |

Notes:

[21] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statisical Analysis 2 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 25mg Q12W |

| | |
|---|---|
| Number of subjects included in analysis | 144 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.4602 [22] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.7 |
| upper limit | 14.8 |

Notes:

[22] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statisical Analysis 3 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q12W |
| Number of subjects included in analysis | 143 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.4429 [23] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | -4.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -15 |
| upper limit | 6.6 |

Notes:

[23] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

| **Statistical analysis title** | Statisical Analysis 4 |
|---|---|
| Comparison groups | Placebo v ARO-APOC3 50mg Q24W |
| Number of subjects included in analysis | 142 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.1763 [24] |
| Method | MMRM |
| Parameter estimate | Difference |
| Point estimate | 7.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.4 |
| upper limit | 18.3 |

Notes:

[24] - MMRM model includes treatment arm, study visit, and baseline value as model terms. The model also includes treatment by visit and treatment by baseline as interaction terms. Observed cases of the data from baseline through Week 48 are included.

## Secondary: Percent Change From Baseline Over Time Through Week 48 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)

| End point title | Percent Change From Baseline Over Time Through Week 48 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) |
|---|---|

End point description:

Full Analysis Set: All randomized participants who receive at least 1 dose of investigational product (IP). n=Participants with an assessment at given time point.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)

| End point values | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | 0.6 (± 3.18) | 5.0 (± 3.67) | 1.1 (± 3.59) | 0.4 (± 3.66) |
| Week 8; n=83, 64, 66, 64, 64 | 1.7 (± 3.24) | 0.7 (± 3.68) | 0.6 (± 3.65) | -3.6 (± 3.69) |
| Week 12; n=80, 63, 61, 64, 61 | 1.8 (± 3.68) | 2.5 (± 4.16) | 2.5 (± 4.18) | 1.6 (± 4.16) |
| Week 16; n=77, 63, 63, 63, 65 | 1.5 (± 3.65) | 2.2 (± 4.11) | 0.4 (± 4.10) | -2.7 (± 4.11) |
| Week 20; n=82, 59, 61, 61, 63 | -0.3 (± 3.78) | 1.3 (± 4.35) | 4.0 (± 4.31) | -3.9 (± 4.33) |
| Week 24; n=81, 61, 63, 62, 61 | -0.1 (± 3.62) | 1.4 (± 4.14) | 3.9 (± 4.10) | -4.3 (± 4.13) |
| Week 28; n=82, 61, 64, 62, 61 | 1.6 (± 3.86) | 0.2 (± 4.42) | 6.1 (± 4.37) | -3.6 (± 4.41) |
| Week 36; n=80, 61, 63, 60, 61 | 1.6 (± 3.80) | 0.0 (± 4.33) | 5.3 (± 4.28) | -3.5 (± 4.35) |
| Week 48; n=78, 60, 64, 61, 61 | 1.7 (± 3.88) | 2.0 (± 4.43) | 6.9 (± 4.32) | -4.0 (± 4.40) |

| End point values | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: percentage change | | | | |
| least squares mean (standard error) | | | | |
| Week 4; n=85, 62, 67, 63, 63 | 3.2 (± 3.67) | | | |
| Week 8; n=83, 64, 66, 64, 64 | 7.4 (± 3.70) | | | |
| Week 12; n=80, 63, 61, 64, 61 | 3.2 (± 4.20) | | | |
| Week 16; n=77, 63, 63, 63, 65 | 3.2 (± 4.09) | | | |
| Week 20; n=82, 59, 61, 61, 63 | 7.2 (± 4.30) | | | |
| Week 24; n=81, 61, 63, 62, 61 | 7.3 (± 4.14) | | | |
| Week 28; n=82, 61, 64, 62, 61 | 2.0 (± 4.42) | | | |
| Week 36; n=80, 61, 63, 60, 61 | 5.7 (± 4.34) | | | |
| Week 48; n=78, 60, 64, 61, 61 | -0.1 (± 4.40) | | | |

| | |
|---|---|
| **Attachments (see zip file)** | Percent Change from Baseline at Week 24 and Over Time |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

| | |
|---|---|
| End point title | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) |

End point description:

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.
TEAEs are AEs that occur following investigational product (IP) administration or a pre-existing condition exacerbated following IP administration.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Up to Week 48

| **End point values** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W | ARO-APOC3 50mg Q12W |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 67 | 67 | 66 |
| Units: participants | | | | |
| All Treatment-Emergent Adverse Events (TEAEs) | 55 | 46 | 45 | 47 |
| Treatment-related TEAEs | 8 | 7 | 9 | 12 |
| Serious TEAEs | 5 | 2 | 5 | 7 |
| TEAEs leading to study drug discontinuation | 2 | 0 | 0 | 1 |
| Deaths | 0 | 0 | 1 | 2 |

| **End point values** | ARO-APOC3 50mg Q24W | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 66 | | | |
| Units: participants | | | | |
| All Treatment-Emergent Adverse Events (TEAEs) | 49 | | | |
| Treatment-related TEAEs | 8 | | | |

| | | | | |
|---|---|---|---|---|
| Serious TEAEs | 5 | | | |
| TEAEs leading to study drug discontinuation | 0 | | | |
| Deaths | 1 | | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: Up to Week 48 | |
| Assessment type | Systematic |
| **Dictionary used** | |
| Dictionary name | MedDRA |
| Dictionary version | 24.0 |
| **Reporting groups** | |
| Reporting group title | Placebo |
| Reporting group description: Volume-matched placebo at Day 1 and Week 12 | |
| Reporting group title | ARO-APOC3 10 mg Q12W |
| Reporting group description: ARO-APOC3 10 mg at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 25mg Q12W |
| Reporting group description: ARO-APOC3 25 mg at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 50mg Q12W |
| Reporting group description: ARO-APOC3 50 mg (n=60) or volume-matched placebo (n=20) at Day 1 and Week 12 (Q12W) | |
| Reporting group title | ARO-APOC3 50mg Q24W |
| Reporting group description: ARO-APOC3 50 mg at Day 1 and Week 24 (Q24W) | |

| Serious adverse events | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 87 (5.75%) | 2 / 67 (2.99%) | 5 / 67 (7.46%) |
| number of deaths (all causes) | 0 | 0 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Parathyroid tumour benign | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |

| | | | |
|---|---|---|---|
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Artery dissection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|---|---|---|---|
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meniscus injury | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Lacunar infarction | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Coeliac artery aneurysm | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal abscess | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| COVID-19 | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Postoperative wound infection | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | ARO-APOC3 50mg Q12W | ARO-APOC3 50mg Q24W | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 66 (10.61%) | 5 / 66 (7.58%) | |
| number of deaths (all causes) | 2 | 1 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Parathyroid tumour benign | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Aortic aneurysm rupture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Artery dissection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Completed suicide | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femur fracture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meniscus injury | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Lacunar infarction | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Coeliac artery aneurysm | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal abscess | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic shock | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| **Non-serious adverse events** | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25mg Q12W |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 55 / 87 (63.22%) | 47 / 67 (70.15%) | 44 / 67 (65.67%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Adrenal adenoma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Benign neoplasm of skin | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blepharal papilloma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Fibroma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Lipoma | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Malignant melanoma in situ | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 2 / 67 (2.99%) | 2 / 67 (2.99%) |
| occurrences (all) | 3 | 2 | 2 |
| Blood pressure inadequately controlled | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aortic aneurysm | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematoma | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hot flush | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 2 / 67 (2.99%) |
| occurrences (all) | 1 | 1 | 2 |
| Injection site erythema | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 4 | 0 | 1 |
| Oedema | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dystrophic calcification | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Secretion discharge | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sensation of foreign body | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Immune system disorders | | | |
| Food allergy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Social circumstances | | | |
| Postmenopause | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erectile dysfunction | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fibrocystic breast disease | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Prostatomegaly | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Emphysema | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 2 / 67 (2.99%) |
| occurrences (all) | 1 | 1 | 2 |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Asthma | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hydrothorax | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Acquired diaphragmatic eventration | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Bronchial hyperreactivity | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Chronic obstructive pulmonary disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dry throat | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Obstructive sleep apnoea syndrome | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 2 | 0 | 2 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 0 | 2 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Bipolar disorder | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Depression | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Investigations | | | |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 87 (2.30%) | 2 / 67 (2.99%) | 1 / 67 (1.49%) |
| occurrences (all) | 2 | 2 | 1 |
| Amylase increased | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 0 | 1 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 3 / 67 (4.48%) |
| occurrences (all) | 2 | 1 | 3 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 0 | 2 |
| Lipase increased | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 3 / 67 (4.48%) |
| occurrences (all) | 4 | 1 | 3 |
| Pancreatic enzymes increased | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Troponin increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Anion gap increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 2 / 67 (2.99%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 2 | 1 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 2 / 67 (2.99%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Bilirubin conjugated increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Blood insulin increased | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 1 | 2 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Cardiac murmur | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cells in urine | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Electrocardiogram T wave inversion | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Electrocardiogram abnormal | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Haematocrit increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Human metapneumovirus test positive | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Insulin C-peptide increased | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Laboratory test abnormal | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Neutrophil percentage increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| White blood cell count increased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Injury, poisoning and procedural complications | | | |
| Injection related reaction | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Skin laceration | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 2 / 67 (2.99%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Contusion | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 2 / 67 (2.99%) | 1 / 67 (1.49%) |
| occurrences (all) | 3 | 2 | 1 |
| Dental restoration failure | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye contusion | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye injury | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid injury | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Heat exhaustion | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ligament sprain | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 3 / 67 (4.48%) |
| occurrences (all) | 1 | 0 | 3 |
| Lisfranc fracture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Meniscus injury | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle strain | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 0 | 1 |
| Post procedural complication | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 2 / 67 (2.99%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Scratch | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin wound | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stress fracture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Thermal burn | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Traumatic haematoma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wrist fracture | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Arrhythmia supraventricular | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Bundle branch block left | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Left atrial enlargement | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Left ventricular hypertrophy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 0 | 2 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 2 / 67 (2.99%) | 3 / 67 (4.48%) |
| occurrences (all) | 3 | 3 | 3 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Complex regional pain syndrome | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cubital tunnel syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epilepsy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lacunar infarction | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Occipital neuralgia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cerebral artery stenosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Diabetic neuropathy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Dizziness | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 3 | 0 | 1 |
| Loss of consciousness | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Migraine | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 3 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Polyneuropathy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Radiculopathy | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vertebrobasilar insufficiency | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 1 | 0 | 2 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coagulopathy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Eosinophilia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Ear and labyrinth disorders | | | |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatochalasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Myopia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Presbyopia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |

| | | | |
|---|---|---|---|
| Diverticulum intestinal | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 1 | 0 | 2 |
| Enteritis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal ulcer | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 1 | 1 |
| Malabsorption | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 3 |
| Pancreatolithiasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Umbilical hernia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 0 | 1 |

| | | | |
|---|---|---|---|
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Colitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 3 / 67 (4.48%) | 0 / 67 (0.00%) |
| occurrences (all) | 6 | 3 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 0 | 2 |
| Gastritis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 2 / 67 (2.99%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Gastrointestinal pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Haemorrhoids | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Intestinal polyp | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Large intestine polyp | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-alcoholic fatty liver | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic cyst | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Hepatic steatosis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hepatomegaly | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Actinic keratosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rosacea | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermal cyst | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermatitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Hidradenitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus allergic | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 1 | 0 | 2 |
| Sebaceous hyperplasia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypertonic bladder | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Renal cyst | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 1 | 1 |
| Ureterolithiasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urethral stenosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Dysuria | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Endocrine disorders | | | |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Thyroid mass | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 3 / 87 (3.45%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 5 | 0 | 1 |
| Osteoarthritis | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 2 | 1 | 1 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 2 / 67 (2.99%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 2 | 1 |
| Diffuse idiopathic skeletal hyperostosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Osteopenia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 0 | 1 |
| Back pain | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 2 / 67 (2.99%) | 2 / 67 (2.99%) |
| occurrences (all) | 2 | 2 | 2 |
| Bursitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Exostosis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mixed connective tissue disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Nodal osteoarthritis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Periarthritis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Scleroderma | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Spondylolisthesis | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Infections and infestations | | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 7 / 87 (8.05%) | 3 / 67 (4.48%) | 7 / 67 (10.45%) |
| occurrences (all) | 8 | 3 | 7 |
| COVID-19 | | | |
| subjects affected / exposed | 12 / 87 (13.79%) | 8 / 67 (11.94%) | 11 / 67 (16.42%) |
| occurrences (all) | 12 | 8 | 11 |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 4 / 67 (5.97%) | 2 / 67 (2.99%) |
| occurrences (all) | 1 | 4 | 2 |
| Cystitis | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 4 / 67 (5.97%) | 2 / 67 (2.99%) |
| occurrences (all) | 5 | 4 | 3 |

| | | | |
|---|---|---|---|
| Sinusitis | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 0 / 67 (0.00%) | 2 / 67 (2.99%) |
| occurrences (all) | 2 | 0 | 2 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 7 / 87 (8.05%) | 4 / 67 (5.97%) | 6 / 67 (8.96%) |
| occurrences (all) | 8 | 4 | 6 |
| Abscess neck | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Acute sinusitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 0 | 1 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Viral pharyngitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abscess oral | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bacteriuria | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Body tinea | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermatophytosis of nail | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Diarrhoea infectious | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fungal skin infection | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Helicobacter infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 2 / 67 (2.99%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |

| | | | |
|---|---|---|---|
| Laryngitis | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Localised infection | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 1 | 0 | 1 |
| Meningitis viral | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 87 (2.30%) | 2 / 67 (2.99%) | 1 / 67 (1.49%) |
| occurrences (all) | 2 | 2 | 1 |
| Otitis media | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Otitis media acute | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 4 / 87 (4.60%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 4 | 0 | 2 |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Post-acute COVID-19 syndrome | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyuria | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Skin infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 0 | 1 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 1 / 67 (1.49%) |
| occurrences (all) | 0 | 2 | 1 |
| Metabolism and nutrition disorders | | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 4 / 87 (4.60%) | 5 / 67 (7.46%) | 4 / 67 (5.97%) |
| occurrences (all) | 4 | 5 | 4 |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperlipidaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Acidosis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 2 / 67 (2.99%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 2 | 2 |
| Hypochloraemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Impaired fasting glucose | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lactose intolerance | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 87 (0.00%) | 1 / 67 (1.49%) | 0 / 67 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 1 / 87 (1.15%) | 0 / 67 (0.00%) | 0 / 67 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 87 (0.00%) | 2 / 67 (2.99%) | 2 / 67 (2.99%) |
| occurrences (all) | 0 | 2 | 2 |

| **Non-serious adverse events** | ARO-APOC3 50mg Q12W | ARO-APOC3 50mg Q24W | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 48 / 66 (72.73%) | 48 / 66 (72.73%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 4 | |
| Adrenal adenoma | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Benign neoplasm of skin | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blepharal papilloma | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Fibroma | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Lipoma | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Malignant melanoma in situ | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 3 / 66 (4.55%) | |
| occurrences (all) | 1 | 3 | |
| Blood pressure inadequately controlled | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hot flush | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Injection site erythema | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 2 / 66 (3.03%) | |
| occurrences (all) | 1 | 3 | |
| Chest discomfort | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Oedema | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Swelling face | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Dystrophic calcification | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Injection site pain | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Injection site reaction | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Secretion discharge | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Sensation of foreign body | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Immune system disorders | | | |

| | | | |
|---|---|---|---|
| Food allergy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Social circumstances | | | |
| Postmenopause | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Erectile dysfunction | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Fibrocystic breast disease | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Prostatomegaly | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Emphysema | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 3 / 66 (4.55%) | |
| occurrences (all) | 1 | 4 | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |

| | | | | |
|---|---|---|---|---|
| Asthma | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Hydrothorax | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Upper respiratory tract inflammation | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 1 | 1 | | |
| Acquired diaphragmatic eventration | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Bronchial hyperreactivity | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Bronchiectasis | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Chronic obstructive pulmonary disease | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Dry throat | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Obstructive sleep apnoea syndrome | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Oropharyngeal pain | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| Rhinorrhoea | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Upper-airway cough syndrome | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Bipolar disorder | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Depression | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Investigations | | | |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 2 / 66 (3.03%) | |
| occurrences (all) | 2 | 2 | |
| Amylase increased | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 3 / 66 (4.55%) | 1 / 66 (1.52%) | |
| occurrences (all) | 3 | 1 | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 2 | |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Blood urea increased | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Glomerular filtration rate decreased | | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 2 | 2 | | |
| Haemoglobin decreased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Lipase increased | | | | |
| subjects affected / exposed | 3 / 66 (4.55%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 4 | 1 | | |
| Pancreatic enzymes increased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Troponin increased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Weight decreased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Alanine aminotransferase increased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Anion gap increased | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| Aspartate aminotransferase increased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Bilirubin conjugated increased | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| Blood bilirubin increased | | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 3 | 0 | | |

| | | | | |
|---|---|---|---|---|
| Blood glucose increased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Blood insulin increased | | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 2 | 0 | | |
| Blood iron decreased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Blood lactate dehydrogenase increased | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| Blood uric acid increased | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| C-reactive protein increased | | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 2 | 0 | | |
| Cardiac murmur | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Cells in urine | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Electrocardiogram T wave inversion | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| Electrocardiogram abnormal | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Gamma-glutamyltransferase increased | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| Haematocrit increased | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Human metapneumovirus test positive | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Insulin C-peptide increased | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Laboratory test abnormal | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| White blood cell count increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Injection related reaction | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Contusion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dental restoration failure | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Eye contusion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Eye injury | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Eyelid injury | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Fall | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hand fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Heat exhaustion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Ligament sprain | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Limb injury | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Lisfranc fracture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Meniscus injury | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Muscle strain | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Post procedural complication | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Scratch | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Skin wound | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Stress fracture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Thermal burn | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Traumatic haematoma | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Wrist fracture | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Arrhythmia supraventricular | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Bundle branch block left | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Left atrial enlargement | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Left ventricular hypertrophy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Palpitations | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|---|---|---|
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 4 / 66 (6.06%) | 5 / 66 (7.58%) | |
| occurrences (all) | 5 | 8 | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Complex regional pain syndrome | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Cubital tunnel syndrome | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 2 | |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 2 | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Lacunar infarction | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Occipital neuralgia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Sciatica | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Syncope | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Cerebral artery stenosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Diabetic neuropathy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Migraine | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Polyneuropathy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Presyncope | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Radiculopathy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vertebrobasilar insufficiency | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Coagulopathy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Ear and labyrinth disorders | | | |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Dermatochalasis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Myopia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Dry eye | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Eye pain | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Presbyopia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Gastrointestinal disorders | | | |
| Diverticulum intestinal | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Abdominal pain | | | |
| subjects affected / exposed | 4 / 66 (6.06%) | 1 / 66 (1.52%) | |
| occurrences (all) | 4 | 1 | |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Enteritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |

| | | | | |
|---|---|---|---|---|
| Gastrointestinal ulcer | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Gastrooesophageal reflux disease | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Malabsorption | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Nausea | | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 2 | 1 | | |
| Pancreatolithiasis | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 0 | 1 | | |
| Umbilical hernia | | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 1 | 1 | | |
| Vomiting | | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 1 / 66 (1.52%) | | |
| occurrences (all) | 2 | 1 | | |
| Abdominal pain upper | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Colitis | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Constipation | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Diarrhoea | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |
| Dysphagia | | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | | |
| occurrences (all) | 0 | 0 | | |

| | | | |
|---|---|---|---|
| Flatulence | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Gastritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Gastrointestinal pain | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Inguinal hernia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Intestinal polyp | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Large intestine polyp | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|---|---|---|
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 2 | |
| Non-alcoholic fatty liver | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Hepatic cyst | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hepatic steatosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hepatomegaly | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 2 | |
| Rosacea | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Alopecia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dermal cyst | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hidradenitis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Onychoclasis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pruritus allergic | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Rash | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Sebaceous hyperplasia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Urticaria | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 2 / 66 (3.03%) | |
| occurrences (all) | 2 | 2 | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| Haematuria | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 1 / 66 (1.52%) | |
| occurrences (all) | 2 | 1 | |
| Hypertonic bladder | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Renal cyst | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Ureterolithiasis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Urethral stenosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Leukocyturia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Proteinuria | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|---|---|---|
| Endocrine disorders | | | |
| Hyperparathyroidism | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Thyroid mass | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 4 / 66 (6.06%) | |
| occurrences (all) | 2 | 5 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 3 / 66 (4.55%) | |
| occurrences (all) | 0 | 3 | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Diffuse idiopathic skeletal hyperostosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Osteopenia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Rotator cuff syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Arthritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Back pain | | | |
| subjects affected / exposed | 4 / 66 (6.06%) | 0 / 66 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| Bursitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Exostosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Flank pain | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Mixed connective tissue disease | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Neck pain | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nodal osteoarthritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Periarthritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Scleroderma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Spondylolisthesis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Infections and infestations | | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 9 / 66 (13.64%) | |
| occurrences (all) | 2 | 10 | |
| COVID-19 | | | |
| subjects affected / exposed | 9 / 66 (13.64%) | 6 / 66 (9.09%) | |
| occurrences (all) | 9 | 6 | |
| Bronchitis | | | |
| subjects affected / exposed | 3 / 66 (4.55%) | 5 / 66 (7.58%) | |
| occurrences (all) | 3 | 5 | |
| Cystitis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 4 / 66 (6.06%) | |
| occurrences (all) | 2 | 7 | |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 4 / 66 (6.06%) | |
| occurrences (all) | 0 | 4 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 2 / 66 (3.03%) | |
| occurrences (all) | 1 | 2 | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 2 / 66 (3.03%) | |
| occurrences (all) | 0 | 2 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 6 / 66 (9.09%) | 2 / 66 (3.03%) | |
| occurrences (all) | 7 | 3 | |
| Abscess neck | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| Acute sinusitis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Ear infection | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 2 | |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Viral pharyngitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Abscess oral | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Bacteriuria | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Body tinea | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|---|---|---|---|
| Dermatophytosis of nail | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Diarrhoea infectious | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Fungal skin infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Helicobacter infection | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Influenza | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Localised infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Meningitis viral | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Otitis media | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|---|---|---|---|
| Otitis media acute | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Paronychia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pharyngitis | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 0 / 66 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Post-acute COVID-19 syndrome | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pyuria | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Skin infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tinea versicolour | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|---|---|---|---|
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Viral infection | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Metabolism and nutrition disorders | | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 8 / 66 (12.12%) | 11 / 66 (16.67%) | |
| occurrences (all) | 8 | 11 | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 2 | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 2 / 66 (3.03%) | 1 / 66 (1.52%) | |
| occurrences (all) | 2 | 1 | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 2 | 1 | |
| Hyperlipidaemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 1 / 66 (1.52%) | |
| occurrences (all) | 0 | 1 | |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 1 / 66 (1.52%) | |
| occurrences (all) | 1 | 1 | |
| Acidosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hyperglycaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hyperuricaemia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hypochloraemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 66 (1.52%) | 0 / 66 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Impaired fasting glucose | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Lactose intolerance | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 66 (0.00%) | 0 / 66 (0.00%) | |
| occurrences (all) | 0 | 0 | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 17 May 2022 | - Requirements for the study design to strengthen reporting criteria for SAEs<br>- Amend requirements to suspend dosing in subjects<br>- To allow a documented prior history of elevated TG between ≥150 mg/dL and ≤499 mg/dL (≥1.69 and ≤5.64 mmol/L) on 1 occasion is adequate to identify the study population targeted for inclusion<br>- To extend the timeframe between the first and second qualifying fasting TG collection by 3 days<br>- Inclusion criteria were updated to allow use of anticoagulation therapy, thyroid hormone therapy, and testosterone replacement therapy.<br>- The PK endpoint was clarified and was redefined as an exploratory endpoint because it is not a main focus of the study.<br>- Additional details were available regarding the primary analysis method and secondary endpoint<br>analysis. Clarified the timing of the final clinical study report.<br>- Updated the table and footnotes in the schedule of events table to clarify assessments and associated timepoints and to be consistent with updated sections of the protocol.<br>- Included the final results from clinical study AROAPOC31001.<br>- Added a new subsection to describe Benefit-Risk assessment for plozasiran.<br>- Clarification that the timepoint begins with the lipid parameter collected at the Week 24 visit.<br>- Time window for Screening visit 3 was extended to 17 days to lessen study burden on study subjects and investigative site staff. Text was updated to more accurately describe dosing visits.<br>- Added guidance regarding the method to determine LDL-C eligibility.<br>- To clarify that use of spermicide is not required when using a condom.<br>- Updated the reporting requirements for pregnancy for consistency with existing procedure. |
| 17 May 2022 | (continued)<br>- Updated that Day 1 predose assessment and 2 fasting TG values during the Screening period was to account for result fluctuations and provide a more stable measurement to represent the baseline TG level. Additional details were available regarding the statistical analyses, including the estimand<br>(ICH E9 [R1] addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials), the baseline\definition for lipid-related lipoprotein and serum PD assessments.<br>- Updated study discontinuation criteria.<br>- Added measures taken to protect personal data collected in the course of study conduct |
| 22 November 2022 | - Added text to footnote 6 of the SOA: HbA1c was to be evaluated on an ongoing basis against<br>treatment discontinuation criteria (Appendix 3).<br>- Definition of HbA1c revised from “Glycosylated hemoglobin” to “Glycated hemoglobin”. Added OLE to the list.<br>- Added guidelines for new study drug discontinuation rules in response to HbA1c elevation.<br>- Added mitigation steps and reference to study drug discontinuation criteria in response HbA1c elevation.<br>- Provided information on the administrative analysis and the increased HbA1c levels in relation to Benefit-Risk analysis.<br>- Added the following text: “In response to diabetes evaluations, adjustments to treatment medication are allowed at the discretion of the PI”.<br>- Added new Appendix 3. |

| | |
|---|---|
| 26 January 2023 | - Added text describing a planned interim analysis. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported